title: Variability in P-glycoprotein inhibitory potency (IC₅₀) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria.
abstract: A P-glycoprotein (P-gp) IC₅₀ working group was established with 23 participating pharmaceutical and contract research laboratories and one academic institution to assess interlaboratory variability in P-gp IC₅₀ determinations. Each laboratory followed its in-house protocol to determine in vitro IC₅₀ values for 16 inhibitors using four different test systems: human colon adenocarcinoma cells (Caco-2; eleven laboratories), Madin-Darby canine kidney cells transfected with MDR1 cDNA (MDCKII-MDR1; six laboratories), and Lilly Laboratories Cells--Porcine Kidney Nr. 1 cells transfected with MDR1 cDNA (LLC-PK1-MDR1; four laboratories), and membrane vesicles containing human P-glycoprotein (P-gp; five laboratories). For cell models, various equations to calculate remaining transport activity (e.g., efflux ratio, unidirectional flux, net-secretory-flux) were also evaluated. The difference in IC₅₀ values for each of the inhibitors across all test systems and equations ranged from a minimum of 20- and 24-fold between lowest and highest IC₅₀ values for sertraline and isradipine, to a maximum of 407- and 796-fold for telmisartan and verapamil, respectively. For telmisartan and verapamil, variability was greatly influenced by data from one laboratory in each case. Excluding these two data sets brings the range in IC₅₀ values for telmisartan and verapamil down to 69- and 159-fold. The efflux ratio-based equation generally resulted in severalfold lower IC₅₀ values compared with unidirectional or net-secretory-flux equations. Statistical analysis indicated that variability in IC₅₀ values was mainly due to interlaboratory variability, rather than an implicit systematic difference between test systems. Potential reasons for variability are discussed and the simplest, most robust experimental design for P-gp IC₅₀ determination proposed. The impact of these findings on drug-drug interaction risk assessment is discussed in the companion article (Ellens et al., 2013) and recommendations are provided.
authors.affiliation: Department of Biology, Drexel University, Philadelphia, PA, USA.
authors.forename: Joe
authors.initials: J
authors.lastname: Bentz
authors.forename: Michael P
authors.initials: MP
authors.lastname: O'Connor
authors.forename: Dallas
authors.initials: D
authors.lastname: Bednarczyk
authors.forename: Joann
authors.initials: J
authors.lastname: Coleman
authors.forename: Caroline
authors.initials: C
authors.lastname: Lee
authors.forename: Johan
authors.initials: J
authors.lastname: Palm
authors.forename: Y Anne
authors.initials: YA
authors.lastname: Pak
authors.forename: Elke S
authors.initials: ES
authors.lastname: Perloff
authors.forename: Eric
authors.initials: E
authors.lastname: Reyner
authors.forename: Praveen
authors.initials: P
authors.lastname: Balimane
authors.forename: Marie
authors.initials: M
authors.lastname: Brännström
authors.forename: Xiaoyan
authors.initials: X
authors.lastname: Chu
authors.forename: Christoph
authors.initials: C
authors.lastname: Funk
authors.forename: Ailan
authors.initials: A
authors.lastname: Guo
authors.forename: Imad
authors.initials: I
authors.lastname: Hanna
authors.forename: Krisztina
authors.initials: K
authors.lastname: Herédi-Szabó
authors.forename: Kate
authors.initials: K
authors.lastname: Hillgren
authors.forename: Libin
authors.initials: L
authors.lastname: Li
authors.forename: Evelyn
authors.initials: E
authors.lastname: Hollnack-Pusch
authors.forename: Masoud
authors.initials: M
authors.lastname: Jamei
authors.forename: Xuena
authors.initials: X
authors.lastname: Lin
authors.forename: Andrew K
authors.initials: AK
authors.lastname: Mason
authors.forename: Sibylle
authors.initials: S
authors.lastname: Neuhoff
authors.forename: Aarti
authors.initials: A
authors.lastname: Patel
authors.forename: Lalitha
authors.initials: L
authors.lastname: Podila
authors.forename: Emile
authors.initials: E
authors.lastname: Plise
authors.forename: Ganesh
authors.initials: G
authors.lastname: Rajaraman
authors.forename: Laurent
authors.initials: L
authors.lastname: Salphati
authors.forename: Eric
authors.initials: E
authors.lastname: Sands
authors.forename: Mitchell E
authors.initials: ME
authors.lastname: Taub
authors.forename: Jan-Shiang
authors.initials: JS
authors.lastname: Taur
authors.forename: Dietmar
authors.initials: D
authors.lastname: Weitz
authors.forename: Heleen M
authors.initials: HM
authors.lastname: Wortelboer
authors.forename: Cindy Q
authors.initials: CQ
authors.lastname: Xia
authors.forename: Guangqing
authors.initials: G
authors.lastname: Xiao
authors.forename: Jocelyn
authors.initials: J
authors.lastname: Yabut
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Yamagata
authors.forename: Lei
authors.initials: L
authors.lastname: Zhang
authors.forename: Harma
authors.initials: H
authors.lastname: Ellens
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000037:antagonists & inhibitors*; D000818:Animals; D001692:Biological Transport; D018938:Caco-2 Cells; D004077:Digoxin / Q000493:pharmacokinetics*; D004285:Dogs; D004347:Drug Interactions; D006801:Humans; D020128:Inhibitory Concentration 50; D018374:LLC-PK1 Cells; D025341:Principal Component Analysis; D018570:Risk Assessment; D013552:Swine
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D004077:Digoxin